Related Experiment Video
Updated: May 17, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Landmarks in hormonal therapy for prostate cancer
Peter Hammerer1, Stephan Madersbacher
1Department of Urology, Academic Hospital Braunschweig, Vienna, Austria. p.hammerer@klinikumbraunschweig.de
Abstract:
• It is >70 years since the responsiveness of symptomatic metastatic prostate cancer to androgen deprivation was first demonstrated. • Since those pivotal studies, progress in hormonal therapy of prostate cancer has been marked by several important developments and the availability of various androgen-suppressing agents. • Treatment guidelines have continued to evolve with clinical and therapeutic progress, but androgen-deprivation therapy (ADT) remains the standard of care for non-localised prostate cancer. • Because of the long-term experience (>20 years) and wealth of evidence from the large number of clinical trials, the luteinizing hormone-releasing hormone (LHRH) agonists are currently the main forms of ADT. • Treatment strategies should be adapted to the individual patient in terms of timing, duration and choice of agent. • Prostate cancer remains the most common type of cancer in men and the development of castration-resistant disease seems inevitable, which together drive the clear and continuing need for new, effective agents for ADT to be used alongside the LHRH agonists.
Insights
Androgen-deprivation therapy (ADT) is standard for advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists widely used. New agents are needed as castration-resistant disease is inevitable.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Prostate cancer is the most common cancer in men.
- Androgen deprivation therapy (ADT) has been the standard of care for over 70 years.
- Luteinizing hormone-releasing hormone (LHRH) agonists are the primary form of ADT due to extensive evidence.
Purpose of the Study:
- To review the evolution and current status of ADT in prostate cancer management.
- To highlight the importance of personalized treatment strategies.
- To emphasize the ongoing need for novel therapeutic agents.
Main Methods:
- Review of historical data and clinical trial evidence.
- Analysis of treatment guidelines and therapeutic progress.
- Discussion of current ADT modalities and future directions.
Main Results:
- ADT remains the cornerstone for non-localized prostate cancer.
- LHRH agonists are the established standard of care for ADT.
- Individualized treatment approaches are crucial for optimal outcomes.
Conclusions:
- Despite advances, ADT is essential for prostate cancer treatment.
- The development of castration-resistant prostate cancer necessitates new therapeutic agents.
- Continued research into novel ADT agents is critical for improving patient survival and quality of life.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...